Evidence map›Paper›PMID 38799089›Full record

ArticleIJTLD open2024

Characteristics of TPT initiation and completion among people living with HIV.

L Gunde, A Wang, D Payne, S O'Connor, A Kabaghe, N Kalata, A Maida, D Kayira, V Buie, L Tauzi and 18 more

Abstract read
In one paragraph

Article in IJTLD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Launch ofIJTLD open · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

L GundeU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
A WangU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
D PayneU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
S O'ConnorU.S. CDC, Atlanta, USA.
A KabagheU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
N KalataU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
A MaidaU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
D KayiraU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
V BuieU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
L TauziLighthouse Trust, Lilongwe, Malawi.
A SankhaniLighthouse Trust, Lilongwe, Malawi.
A ThawaniLighthouse Trust, Lilongwe, Malawi.
E RambikiLighthouse Trust, Lilongwe, Malawi.
A AhimbisibweElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lilongwe, Malawi.
T MaphosaElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lilongwe, Malawi.
K KudiaborElizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lilongwe, Malawi.
R NyirendaDepartment of HIV/AIDS, STI and Viral Hepatitis, Ministry of Health, Lilongwe, Malawi.
J MpungaNational TB and Leprosy Elimination Program, Ministry of Health, Lilongwe, Malawi.
K MbenderaNational TB and Leprosy Elimination Program, Ministry of Health, Lilongwe, Malawi.
P NyasuluDepartment of HIV/AIDS, STI and Viral Hepatitis, Ministry of Health, Lilongwe, Malawi.
F KayigambaICAP Global Health, Lilongwe, Malawi.
M FarahaniICAP at Columbia University, New York, USA.
A C VoetschU.S. CDC, Atlanta, USA.
K BrownU.S. CDC, Atlanta, USA.
A JahnDepartment of HIV/AIDS, STI and Viral Hepatitis, Ministry of Health, Lilongwe, Malawi.
B GirmaNational TB and Leprosy Elimination Program, Ministry of Health, Lilongwe, Malawi.
K MirkovicU.S. Centers for Disease Control and Prevention (CDC), Lilongwe, Malawi.
MPHIA Survey Team

Funding

Malawi HIV Implementation Research Scientist Training Program (MHIRST)D43TW010060 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MINA CHRISTINE HOSSEINIPOUR, Victor Mwapasa · 2015 to 2026
$3.8M
CGH CDC HHS NU2GGH002173FIC NIH HHS D43 TW010060
6 · The paper itself

Abstract

backgroundTB preventive treatment (TPT) reduces morbidity and mortality among people living with HIV (PLHIV). Despite the successful scale-up of TPT in Malawi, monitoring and evaluation have been suboptimal. We utilized the Malawi Population-Based HIV Impact Assessment (MPHIA) 2020-2021 survey data to estimate TPT uptake and completion among self-reported HIV-positive persons.

methodsWe estimated the proportion of HIV-positive respondents who had ever undergone TPT, and determined the percentage of those currently on TPT who had completed more than 6 months of treatment. Bivariate and multivariable logistic regression were performed to calculate the odds ratios for factors associated with ever-taking TPT. All variables were self-reported, and the analysis was weighted and accounted for in the survey design.

resultsOf the HIV+ respondents, 38.8% (95% CI 36.4-41.3) had ever taken TPT. The adjusted odds of ever taking TPT were 8.0 and 5.2 times as high in the Central and Southern regions, respectively, compared to the Northern region; 1.9 times higher among those in the highest wealth quintile, and 2.1 times higher for those on antiretroviral therapy >10 years. Of those currently taking TPT, 56.2% completed >6 months of TPT.

conclusionThese results suggest low TPT uptake and >6 months' completion rates among self-reported HIV+ persons. Initiatives to create demand and strengthen adherence would improve TPT uptake.

Indexed as

epidemiologypreventiontuberculosis

Identifiers

PMID38799089
PMCPMC11119003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.